Cogentum client Acrux today announced one of the biggest licensing  deals in Australian Biotech history. The deal with Eli Lilly ranks up there as one of the biggest outcomes for an Australian biotech. From the announcements you will see that this is a superb result for any Australian company seeking to license it’s technology.

Cogentum worked closely with Acrux through the Axiron development stage to validate the market potential of the technology and gain a cogent understanding of its likely  acceptance and adoption by US based physicians and patients.  Ensuring that the company had sound and objective evidence to support the  proposition that Axiron was an attractive and compelling product formed  a critical part of building the case to investors, regulators and of course, potential licensees. As Acrux CEO Dr Richard Treagus commented previously about the work undertaken by Cogentum, “Your results have elevated our negotiating position exponentially.”

Cogentum would like to congratulate the entire Acrux team, led by Dr Richard Treagus on the seamless execution of a breakthrough strategy that sets a new benchmark for Australian biotech.

We strongly believe that Acrux shows a  clear way forward for Australian Biotech companies seeking to commercialise their technology. The value of a rational market orientated approach that validates the market need and creates  strong alignment between the need and the clinical and business development activities is now clear –   outstanding results for investors.  We are thrilled for both the entire Acrux team and their investors as this is just reward for their focus, patience and diligence.